Caribou Biosciences, Inc.

CRBU

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001619856

D

fourth fifth of 369 graded peers in healthcare

rank 236 of 369; percentile 63.9; sampling error 2.5 points; lower is stronger

A B C D E


D, the sloth



Scoreboard


Profitability	B percentile 29.5
Solvency	C/D percentile 59.1
Growth and financing	D percentile 70.2
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $175.4M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	short runway not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 5, 2026 245 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026
Last close	$0.44 2026-11-04; market equity $47.6M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats ("CRISPR") genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our genome-editing platform is based on our novel chRDNA (CRISPR hybrid RNA-DNA, or "chRDNA," pronounced "chardonnay") genome-editing technology, which enables more precise genome editing of allogeneic cell therapies.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 29.5						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(15.2%)	(6.6%)	29.5	801	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 59.1					
Twelve-month failure probability	0.83%	0.08%	83.9	249	2026-06-30
Altman Z double-prime	(9.88)	(0.35)	61.5	746	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	5.71x	2.92x	31.8	827	2025-12-31
Growth and financing, sleeve percentile 70.2					
Revenue growth, three-year compound	(7.0%)	10.1%	83.2	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	(22.3%)	2.2%	86.2	696	2025-12-31
Net share issuance, one year	3.9%	2.5%	41.2	630	2026-02-27


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.3 months

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
231	Beam Therapeutics Inc. (BEAM)	62.5	C/D	
232	AbbVie Inc. (ABBV)	62.8	D	
233	Royalty Pharma plc (RPRX)	63.0	D	
234	Integra Lifesciences Holdings Corp. (IART)	63.3	D	
235	Arvinas, Inc. (ARVN)	63.6	D	fortress balance sheet
236	Caribou Biosciences, Inc. (CRBU)	63.9	D	short runway
237	Organogenesis Holdings Inc. (ORGO)	64.1	D	fortress balance sheet
238	Lenz Therapeutics, Inc. (LENZ)	64.4	D	short runway
239	Entera Bio Ltd. (ENTX)	64.7	D	degenerate inputs
240	Fulgent Genetics, Inc. (FLGT)	64.9	D	short runway
241	Dentsply Sirona Inc. (XRAY)	65.2	D	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-04 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(47.5%)	(2.2%)	16
Distance from 52-week high	(81.7%)	(26.8%)	8
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	(235.8%)	(0.9%)	3
Book value to price	2.06	0.27	95
Sales to price	0.23	0.28	43
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.81)	(0.19)	16

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$26.2M
Operating cash flow, four quarters	-$95.8M
Months of runway	3.3
Days since last periodic filing	84 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	$1.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$148.1M	2025-12-31	2026-03-05	10-K	26-000008
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$111.0M	2025-12-31	2026-03-05	10-K	26-000008
3	assets	us-gaap:Assets	$175.4M	2025-12-31	2026-03-05	10-K	26-000008
4	assets	us-gaap:Assets	$313.3M	2024-12-31	2026-03-05	10-K	26-000008
5	current assets	us-gaap:AssetsCurrent	$145.2M	2025-12-31	2026-03-05	10-K	26-000008
6	current liabilities	us-gaap:LiabilitiesCurrent	$25.4M	2025-12-31	2026-03-05	10-K	26-000008
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$596.5M	2025-12-31	2026-03-05	10-K	26-000008
8	operating income	us-gaap:OperatingIncomeLoss	-$148.3M	2025-12-31	2026-03-05	10-K	26-000008
9	book equity	us-gaap:StockholdersEquity	$122.2M	2025-12-31	2026-03-05	10-K	26-000008
10	liabilities	us-gaap:Liabilities	$53.2M	2025-12-31	2026-03-05	10-K	26-000008
11	operating income	us-gaap:OperatingIncomeLoss	-$67.0M	2021-12-31	2023-03-09	10-K	23-000037
12	interest expense	us-gaap:InterestExpense	$8,000	2021-12-31	2022-03-21	10-K	22-004233
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$11.2M	2025-12-31	2026-03-05	10-K	26-000008
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10.0M	2024-12-31	2026-03-05	10-K	26-000008
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$34.5M	2023-12-31	2025-03-10	10-K	25-000015
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$13.9M	2022-12-31	2024-03-11	10-K	24-000013
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.4M	2025-12-31	2026-03-05	10-K	26-000008
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$138.2M	2024-12-31	2026-03-05	10-K	26-000008

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.9M	2024-12-31	2026-03-05	10-K	26-000008
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$93.3M	2023-12-31	2025-03-10	10-K	25-000015
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$11.6M	2023-12-31	2025-03-10	10-K	25-000015
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$91.0M	2022-12-31	2024-03-11	10-K	24-000013
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$6.5M	2022-12-31	2024-03-11	10-K	24-000013
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$3.6M	2025-12-31	2026-03-05	10-K	26-000008
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$148.7M	2025-12-31	2026-03-05	10-K	26-000008
26	income tax	us-gaap:IncomeTaxExpenseBenefit	-$550,000	2025-12-31	2026-03-05	10-K	26-000008
27	current assets	us-gaap:AssetsCurrent	$219.4M	2024-12-31	2026-03-05	10-K	26-000008
28	current liabilities	us-gaap:LiabilitiesCurrent	$30.7M	2024-12-31	2026-03-05	10-K	26-000008
29	assets	us-gaap:Assets	$432.2M	2023-12-31	2025-03-10	10-K	25-000015
30	assets	us-gaap:Assets	$373.8M	2022-12-31	2024-03-11	10-K	24-000013
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	96,637,202	2026-02-27	2026-03-05	10-K	26-000008
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	93,004,602	2025-03-04	2025-03-10	10-K	25-000015

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.